| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hypersensitivity | D006967 | 22 associated lipids |
| Bacterial Infections | D001424 | 21 associated lipids |
| Anemia | D000740 | 21 associated lipids |
| Vomiting | D014839 | 21 associated lipids |
| Hyperglycemia | D006943 | 21 associated lipids |
| Dermatitis, Allergic Contact | D017449 | 20 associated lipids |
| Translocation, Genetic | D014178 | 20 associated lipids |
| Drug Hypersensitivity | D004342 | 20 associated lipids |
| HIV Infections | D015658 | 20 associated lipids |
| Ataxia | D001259 | 20 associated lipids |
| Gastrointestinal Diseases | D005767 | 20 associated lipids |
| Parkinsonian Disorders | D020734 | 20 associated lipids |
| Brain Edema | D001929 | 20 associated lipids |
| Heart Defects, Congenital | D006330 | 20 associated lipids |
| Hypothermia | D007035 | 19 associated lipids |
| Erectile Dysfunction | D007172 | 19 associated lipids |
| Dermatitis, Atopic | D003876 | 19 associated lipids |
| Peptic Ulcer | D010437 | 19 associated lipids |
| Pregnancy Complications | D011248 | 19 associated lipids |
| Cough | D003371 | 19 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Spada M et al. | Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression. | 2006 | Am. J. Transplant. | pmid:16771811 |
| Lemahieu W et al. | Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. | 2005 | Am. J. Transplant. | pmid:15888045 |
| Axelrod D et al. | Reduction of CMV disease with steroid-free immunosuppresssion in simultaneous pancreas-kidney transplant recipients. | 2005 | Am. J. Transplant. | pmid:15888050 |
| Reyes J et al. | Intestinal transplantation under tacrolimus monotherapy after perioperative lymphoid depletion with rabbit anti-thymocyte globulin (thymoglobulin). | 2005 | Am. J. Transplant. | pmid:15888051 |
| Knoop C et al. | Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions. | 2005 | Am. J. Transplant. | pmid:15888057 |
| Kandaswamy R et al. | A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients--an interim analysis. | 2005 | Am. J. Transplant. | pmid:15888064 |
| Saliba F et al. | Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial. | 2017 | Am. J. Transplant. | pmid:28133906 |
| Cosio FG and Larson TS | Cardiovascular disease after transplantation: do we know all of the variables? | 2003 | Am. J. Transplant. | pmid:12859523 |
| de Fijter JW et al. | Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial. | 2017 | Am. J. Transplant. | pmid:28027625 |
| Krämer BK et al. | Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation. | 2003 | Am. J. Transplant. | pmid:12859533 |
| Dugast E et al. | Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients. | 2016 | Am. J. Transplant. | pmid:27367750 |
| Trofe-Clark J et al. | Immunosuppression, generic drugs and the FDA. | 2012 | Am. J. Transplant. | pmid:22176626 |
| Latran M | Response to Klintmalm on the use of generic immunosuppression. | 2012 | Am. J. Transplant. | pmid:22176636 |
| Ellis CL and Racusen LC | Mild rise in creatinine six months post kidney transplant. | 2012 | Am. J. Transplant. | pmid:22845913 |
| Krenzien F et al. | Age-Dependent Metabolic and Immunosuppressive Effects of Tacrolimus. | 2017 | Am. J. Transplant. | pmid:27754593 |
| O'Grady JG et al. | Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. | 2007 | Am. J. Transplant. | pmid:17109723 |
| Böhmig GA et al. | Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. | 2007 | Am. J. Transplant. | pmid:17109725 |
| Hirsch HH et al. | Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study. | 2013 | Am. J. Transplant. | pmid:23137180 |
| Mujtaba MA et al. | Conversion from tacrolimus to belatacept to prevent the progression of chronic kidney disease in pancreas transplantation: case report of two patients. | 2014 | Am. J. Transplant. | pmid:25179306 |
| Naesens M et al. | Tacrolimus exposure and evolution of renal allograft histology in the first year after transplantation. | 2007 | Am. J. Transplant. | pmid:17608835 |
| Klintmalm GB | Immunosuppression, generic drugs and the FDA. | 2011 | Am. J. Transplant. | pmid:21794082 |
| Shihab FS et al. | Effect of corticosteroid withdrawal on tacrolimus and mycophenolate mofetil exposure in a randomized multicenter study. | 2013 | Am. J. Transplant. | pmid:23167508 |
| Alloway RR et al. | A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients. | 2012 | Am. J. Transplant. | pmid:22759200 |
| Wlodarczyk Z et al. | Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. | 2009 | Am. J. Transplant. | pmid:19681813 |
| Chisholm-Burns MA et al. | Immunosuppressant therapy adherence and graft failure among pediatric renal transplant recipients. | 2009 | Am. J. Transplant. | pmid:19681814 |
| Schold JD and Kaplan B | AZA/tacrolimus is associated with similar outcomes as MMF/tacrolimus among renal transplant recipients. | 2009 | Am. J. Transplant. | pmid:19681827 |
| Troppmann C et al. | Impact of portal venous pancreas graft drainage on kidney graft outcome in simultaneous pancreas-kidney recipients reported to UNOS. | 2004 | Am. J. Transplant. | pmid:15023146 |
| Pirenne J et al. | Tolerance of liver transplant patients to strenuous physical activity in high-altitude. | 2004 | Am. J. Transplant. | pmid:15023147 |
| Heisel O et al. | New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. | 2004 | Am. J. Transplant. | pmid:15023151 |
| Hardinger KL et al. | Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing. | 2004 | Am. J. Transplant. | pmid:15023155 |
| Suwelack B et al. | Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. | 2004 | Am. J. Transplant. | pmid:15023160 |
| Busque S et al. | Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. | 2009 | Am. J. Transplant. | pmid:19660021 |
| Meier-Kriesche HU et al. | Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. | 2005 | Am. J. Transplant. | pmid:16095509 |
| Senior PA et al. | Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. | 2005 | Am. J. Transplant. | pmid:16095517 |
| Fan DM et al. | Successful ABO-incompatible living-related intestinal transplantation: a 2-year follow-up. | 2015 | Am. J. Transplant. | pmid:25808777 |
| Borrows R et al. | Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. | 2006 | Am. J. Transplant. | pmid:16433766 |
| Kohnle M et al. | Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. | 2006 | Am. J. Transplant. | pmid:16433776 |
| Larson TS et al. | Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. | 2006 | Am. J. Transplant. | pmid:16468960 |
| Vitko S et al. | Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study. | 2006 | Am. J. Transplant. | pmid:16468962 |
| Knechtle SJ et al. | Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. | 2009 | Am. J. Transplant. | pmid:19344431 |
| Grinyo JM et al. | Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. | 2004 | Am. J. Transplant. | pmid:15268733 |
| Min SI et al. | Conversion of twice-daily tacrolimus to once-daily tacrolimus formulation in stable pediatric kidney transplant recipients: pharmacokinetics and efficacy. | 2013 | Am. J. Transplant. | pmid:23734831 |
| Bunnapradist S et al. | Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. | 2013 | Am. J. Transplant. | pmid:23279614 |
| Ceschi A et al. | Acute calcineurin inhibitor overdose: analysis of cases reported to a national poison center between 1995 and 2011. | 2013 | Am. J. Transplant. | pmid:23279718 |
| Rush D et al. | Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. | 2007 | Am. J. Transplant. | pmid:17908280 |
| Barbas AS et al. | Posterior reversible encephalopathy syndrome independently associated with tacrolimus and sirolimus after multivisceral transplantation. | 2013 | Am. J. Transplant. | pmid:23331705 |
| Gatault P et al. | Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study. | 2017 | Am. J. Transplant. | pmid:27862923 |
| Fujishiro J et al. | Influence of immunosuppression on alloresponse, inflammation and contractile function of graft after intestinal transplantation. | 2010 | Am. J. Transplant. | pmid:20642681 |
| Margreiter R et al. | Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. | 2008 | Am. J. Transplant. | pmid:18510632 |
| Martinez F et al. | High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: Results of the Neo-PDGF Study. | 2010 | Am. J. Transplant. | pmid:20642691 |